article thumbnail

mRNA vaccine 100% effective against deadly bacteria

Drug Discovery World

For the first time, researchers have developed an mRNA vaccine that is 100% effective against a type of bacteria that is lethal to humans, paving the way for effective vaccination against antibiotic-resistant bacteria. However, until now scientists believed that mRNA vaccines against bacteria were biologically undoable.

article thumbnail

Research Roundup: Different Antibody Responses to COVID-19 and More

The Pharma Data

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Link between periodontitis and cardiovascular disease in individuals with rheumatoid arthritis

Scienmag

New research published in Arthritis & Rheumatology suggests that immune responses to certain bacteria that cause periodontal disease may play a role in patients’ higher cardiovascular disease risk. Among 197 patients with rheumatoid arthritis, those with antibody responses to common […].

article thumbnail

Leading innovators in coronavirus vaccine components

Pharmaceutical Technology

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

article thumbnail

This week in drug discovery (8-12 January) 

Drug Discovery World

Perhaps most importantly, a new antibiotic was found that targets a Gram-negative pathogen, mRNA was used as an effective therapy for a rare liver disease, and a common immune cell was found to attack cancer.

Drugs 52
article thumbnail

Mutations leading to omicron variant did not enable virus to fully escape immune system

The Pharma Data

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response.

article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.